

Jornal de  
Pediatria

www.jpmed.com.br



## ORIGINAL ARTICLE

Increase in new-onset type 1 diabetes diagnoses among  
Brazilian children and adolescents during the COVID-19  
pandemicQ1  
Q2

Q3 Renata Szundy Berardo <sup>ID a,\*</sup>, Melanie Rodacki <sup>ID b</sup>, Bruna S. Pugliese <sup>ID a</sup>,  
Fernanda Roisman <sup>ID a</sup>, Juliane Rocha <sup>ID c</sup>, Daniel Gilban <sup>ID c</sup>, Bianca Balassiano <sup>ID c</sup>,  
Cristine Barboza Beltrão <sup>#,d</sup>, Isla Aguiar Paiva <sup>ID d</sup>, Juliana Veiga Moreira <sup>ID d</sup>,  
Jorge Luescher <sup>ID e</sup>, Ludmila Campos <sup>ID e</sup>, Isabella Coutinho <sup>ID e</sup>, Isabel Rey Madeira <sup>ID f</sup>,  
Alessandra S.M.F. da Costa <sup>ID f</sup>, Lucianne R.M. Tannus <sup>ID f</sup>, Nádia C.P. Rodrigues <sup>ID f</sup>,  
Lenita Zajdenverg <sup>ID b</sup>

<sup>a</sup> Hospital Federal dos Servidores do Estado (HFSE) do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

<sup>b</sup> Universidade Federal do Rio de Janeiro (UFRJ), Hospital Universitário Clementino Fraga Filho. Departamento de Medicina Interna, Seção de Nutrologia e Diabetes, Rio de Janeiro, RJ, Brazil

<sup>c</sup> Hospital Geral de Bonsucesso (HGB), Rio de Janeiro, RJ, Brazil

<sup>d</sup> Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione (IEDE), Rio de Janeiro, RJ, Brazil

<sup>e</sup> Universidade Federal do Rio de Janeiro (UFRJ), Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG), Rio de Janeiro, RJ, Brazil

<sup>f</sup> Universidade Estadual do Rio de Janeiro (UERJ), Policlínica Piquet Carneiro, Rio de Janeiro, RJ, Brazil

Received 26 January 2025; accepted 8 April 2025

Available online xxx

## KEYWORDS

T1dm;  
Covid-19;  
Ketoacidosis;  
Epidemiology

## Abstract

**Objective:** This study aimed to determine if there was a rise in new T1DM cases in children during the pandemic in a large metropolitan area in Brazil.

**Methods:** The authors conducted a cross-sectional study at five public tertiary care centers that specialize in diabetes in children, comparing all new T1DM cases (ages 0.5–18y) diagnosed from March 2020 to December 2021 (pandemic period, PP) with those from March 2018 to December 2019 (historical period, HP).

**Results:** There were 167 new cases in the PP compared to 99 in the HP, reflecting a 68.7% rise, with a notable peak observed in the third quarter of 2020 ( $p = 0.006$ ). The average age of diagnosis was  $8.4 \pm 4.2$  years in the PP and  $7.5 \pm 3.6$  years in the HP, with no significant difference ( $p = 0.06$ ). The gender distribution, BMI Z scores, and duration of diabetes symptoms before diagnosis were similar. The incidence of diabetic ketoacidosis (DKA) at onset was elevated but did not

\* Corresponding author.

E-mail: [renataszundy@gmail.com](mailto:renataszundy@gmail.com) (R.S. Berardo).

# 0009–0009–8044–275x

<https://doi.org/10.1016/j.jpmed.2025.04.001>

0021-7557/© 2025 The Author(s). Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Pediatria. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Please cite this article in press as: R.S. Berardo, M. Rodacki, B.S. Pugliese et al., Increase in new-onset type 1 diabetes diagnoses among Brazilian children and adolescents during the COVID-19 pandemic, *Jornal de Pediatria* (2025), <https://doi.org/10.1016/j.jpmed.2025.04.001>

increase during the pandemic (62.6 % historical vs. 59.3 % pandemic period). During the PP, 24 % of patients reported symptoms of SARS-CoV-2 infection before the diagnosis of T1DM or at admission, and 13 % (7/53) of tested patients were positive for SARS-CoV-2.

**Conclusions:** The present findings indicate a significant rise in new T1DM cases among children during the COVID-19 pandemic compared to prior years, without differences in DKA at onset.

© 2025 The Author(s). Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Pediatria. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

## 1 Introduction

2 Since December 2019, the world has been challenged by the  
3 coronavirus disease (COVID-19), which was labeled a global  
4 pandemic on March 11, 2020.

5 In the following years, the understanding of this disease  
6 improved. Vaccinations in many countries have progressed,  
7 reducing the incidence and severity of the disease. However,  
8 long-term consequences have emerged, but the underlying  
9 mechanisms remain largely unexplored.

10 In May 2023, the CDC reported 15,594,079 total child  
11 COVID-19 cases, accounting for 17.9 % of all COVID-19 cases,  
12 with an overall rate of 20,718 cases per 100,000 children in  
13 the population [1].

14 The first confirmed case of COVID-19 in Brazil was  
15 reported on February 25, 2020. Since then, Brazil has  
16 recorded over 34 million cases and 688,000 deaths, making  
17 it the fifth highest worldwide.

18 Rio de Janeiro had the second-largest number of cases in  
19 the country, experiencing five virus waves: the B1 variant  
20 (April-May 2020), Zeta variant (November 2020-January  
21 2021), Gamma variant (February-June 2021), Delta variant  
22 (August 2021), and the Omicron variant (December 2021-  
23 January 2022) [2].

24 Vaccination in Brazil began in January 2021 for selected  
25 adult groups and was expanded to adolescents aged 12–17  
26 in September 2021.

27 The official reports significantly underestimated the inci-  
28 dence of SARS-CoV-2 infection. Brazil ranked 125th globally  
29 in COVID-19 testing as of October 21, and testing was lim-  
30 ited, especially in children, as they often displayed mild or  
31 no symptoms [3].

32 SARS-CoV-2 interacts with host cells by binding to the  
33 angiotensin-converting enzyme 2 (ACE2) on cell membranes  
34 through its spike protein. ACE2 is found in many glands and  
35 organs with endocrine functions. Although COVID-19 typi-  
36 cally has a less severe impact on children compared to  
37 adults, in some cases, it can lead to a systemic response due  
38 to abnormal hyperinflammation, known as multisystem  
39 inflammatory syndrome in children (MIS-C), associated with  
40 high mortality and apparent involvement of the immune sys-  
41 tem [4,5].

42 T1DM is an autoimmune disease potentially triggered by  
43 viral infections [6]. Studies have explored the link between  
44 the COVID-19 pandemic and the onset of T1DM in children,  
45 some reporting an increased incidence of T1DM and severe  
46 diabetic ketoacidosis (DKA), while others found no associa-  
47 tion [7–9]. A meta-analysis indicated a significant rise in  
48 childhood new-onset T1DM, DKA, and higher mean HbA1c  
49 levels during the first year of the pandemic compared to  
50 pre-pandemic [10]. A recent cohort from the TEDDY study

indicated that COVID-19 did not trigger islet-autoantibody  
positivity in these genetically at-risk children [11]. Contra-  
dicting results were found in a similar cohort in which SARS-  
CoV-2 infection was temporally associated with the develop-  
ment of islet autoantibodies [12].

The incidence of T1DM has been rising globally, including  
in Brazil. However, the pandemic's impact on this trend  
remains uncertain. Given Brazil's high number of COVID-19  
cases and the lack of data on new diabetes cases, there is a  
pressing need for further research [13–15].

Healthcare in Brazil is provided by the Unified Health Sys-  
tem (SUS) and a supplementary system, with over 70 % of  
the population using the public system for free care. After  
diabetes diagnosis, children are referred to specialized ter-  
tiary care centers, which are crucial for pediatric T1DM  
treatment in Rio de Janeiro, serving around 6.7 million peo-  
ple as of the 2022 census.

This study aims to compare the number of new T1DM cases  
between 2018–2019 (historical period) and 2020–2021 (pan-  
demic period) at five pediatric tertiary care centers in Rio de  
Janeiro to assess the impact of the pandemic.

## Materials and methods

A multicenter, cross-sectional study compared pediatric  
patients with new-onset T1DM during two periods: March  
2020 to December 2021 (PP - pandemic period) and March  
2018 to December 2019 (HP - historical period). Data was col-  
lected at five centers in Brazil's public healthcare system spe-  
cializing in pediatric T1DM in metropolitan Rio de Janeiro.

The study included children and adolescents (ages  
0.5–18 years) with a new diagnosis of T1DM within the past  
six months, as determined by glycemic criteria and the need  
for insulin, according to the ISPAD guidelines. Children under  
six months of age were excluded to prevent misdiagnosing  
neonatal diabetes [16].

Clinical data were collected from patient medical  
records, including age, gender, age at diabetes diagnosis,  
duration of diabetes symptoms before diagnosis, and body  
weight, height, and BMI from the first outpatient visit.  
Informed consent was obtained from legal guardians and  
patients. The study was approved by the Institutional Ethics  
Committee and registered on Plataforma Brasil. (protocol  
number 000662).

During the pandemic, interviews gathered medical histo-  
ries on COVID-19 symptoms, including infection dates and  
test results (RT-PCR or IgM antibodies), before the diagnosis  
of T1DM.

The pandemic group was divided into confirmed COVID-19  
(positive RT-PCR or IgM/IgG antibodies), suspected

**Table 1** Clinical manifestations of COVID-19 infection in children.

Fever
Cough / Nasal symptoms
Pharyngeal erythema / sore throat
Disturbances of smell or taste
Gastrointestinal symptoms (diarrhea, nausea, vomiting, and abdominal pain)
Headache and malaise
Rash
Conjunctivitis
SARS / Respiratory failure
Pediatric inflammatory multisystem syndrome (PIMs)

(symptoms of COVID-19, without available or positive testing), - Table 1 and neither [4].

## Statistical analysis

The data were analyzed using Statistical Package R Project version 4.2.0. Descriptive statistics are presented as absolute and relative frequencies for categorical variables and mean and standard deviation for quantitative variables. Differences in the frequencies of categorical variables were analyzed using a chi-square or Fisher's exact test. A multinomial model, specifically multinomial logistic regression, was employed to assess differences between groups. The statistical tests applied included maximum likelihood estimation (MLE), Wald tests for the significance of individual coefficients, likelihood ratio tests for model comparison, and the use of confidence intervals to assess the precision of the estimates. The reference groups were the year of diabetes diagnosis (2018) and the 2nd quarter. The year of diagnosis was used as the response variable, and the trimester was used as the explanatory variable.

Student's *t*-test and ANOVA were used to analyze the differences between groups for quantitative variables. The level of statistical significance ( $\alpha$ ) was  $p < 0.05$ .

## Results

### Clinical characteristics and demographics

A total of 300 children were diagnosed with T1DM from 2018 to 2021. During the pandemic period (March 2020 to

December 2021), 167 cases were reported, compared to 99 cases during the historical period (March 2018 to December 2019), representing a 68.7 % increase. This analysis excludes patients from the first quarter of 2018 and 2020.

The average age was 8.12 years, with a median of 8.16 years (range 0.57–18.4 years). Although the pandemic group was slightly older, this difference was no longer statistically significant. During the pandemic, ages ranged from 0.57 to 18.4 years, with first and third quartiles at 5.04 and 11.15 years, respectively. In the historical period, ages ranged from 1 to 15.9 years, with first and third quartiles at 4.63 and 9.8 years.

There was no significant difference in gender distribution or BMI Z scores between the groups (Table 2).

### Diabetic ketoacidosis and symptoms of diabetes

DKA frequency (62.6 % HP vs. 59.3 % PP) and the average duration of classic symptoms (polyuria, polydipsia, nocturia, enuresis, weight loss) before the diagnosis of diabetes (28.8 days historical vs. 28 days pandemic) were similar between groups.

### Seasonal distribution of new T1DM diagnoses

The distribution of diagnoses by quarter and year is illustrated in Figure 1. A significant difference was noted in the distribution of diagnoses across the quarters each year, with a notable increase in 2020. Specifically, there was a substantial increase in the number of new cases of T1DM in the third quarter (Q3) of 2020 compared to 2018 and 2019 ( $p = 0.006$ ). Additionally, in the fourth quarter (Q4), there was a significant increase in new T1DM cases between 2018 and 2020. However, this trend did not continue in 2021.


### SARS-CoV-2 infection symptoms and testing

During the pandemic, 40 out of 167 patients (23.9 %) reported symptoms of SARS-CoV-2 infection prior to T1DM diagnosis, and 20 within two weeks. The average time from suspicion of SARS-CoV-2 infection to diagnosis of diabetes was 38 days (range: 0 to 487 days). The most frequently reported symptoms were abdominal pain (9.63 %), somnolence (8.43 %), cough, and shortness of breath (7.22 % each). Fever, sore throat, and headache were reported in 9 patients each (5.42 %). Six patients (3.6 %) reported ageusia, and 2 reported skin rash.

**Table 2** Demographic and clinical characteristics of historical versus pandemic period patients [1].

	Historical period 2018–2019	Pandemic period 2020–2021	P-value
N patients	99	167	
Average age (years) -mean (SD)	7.5 (3.6)	8.4 (4.2)	0.06
Z-score BMI - mean (SD)	0.3 (1.2)	0.2 (1.2)	0.79
Female sex - n (%)	49 (49.5)	80 (47.9)	0.90
Ketoacidosis (yes) - n (%)	62 (62.6)	99 (59.3)	0.99
Duration of T1DM symptoms before diagnosis - days avg (SD)	28.81 (26.77)	28 (32.43)	0.83

**Q4** <sup>1</sup>Excluded first quarter of 2018 and 2020.



**Figure 1** Distribution of new cases of diabetes each year and quarter.

Of the symptomatic patients, 5 (8%) had a positive test result, 17 (42.5%) tested negative, and 18 were not tested. In three cases, the SARS-CoV-2 antibody status was undetermined, and one result was positive for IgG antibodies. Three patients had positive SARS-CoV-2 RT-PCR concurrent with T1DM diagnosis but were asymptomatic.

None of the patients had been vaccinated at the time of the study.

## Discussion

The present study is the first to examine the effects of the COVID-19 pandemic on new cases of T1DM in children across Latin America, revealing a significant 68.7% increase in cases. While the incidence of T1DM in Brazil has been rising, a national registry for comparison is lacking. However, a study conducted in another city in the Brazilian urban area indicates an annual increase of 3.1% in cases among children under 14 years old from 1986 to 2015. Thus, the pandemic-related increase in new cases is significantly higher than expected.

There is growing evidence that SARS-CoV-2 infection is linked to higher rates of diabetes. A meta-analysis found a 66% increase in new-onset diabetes cases following infection [17], and an excess case above control of 11 to 276% was found in another review [18]. Another meta-analysis of T1DM in youths revealed a higher incidence rate during the first year of the pandemic [19]. In a study evaluating children, there was an increased risk of a new diagnosis of T1DM at 1, 3, and 6 months after SARS-CoV-2 infection, compared with other respiratory infections [20]. A study using DPV data demonstrated an excess number of new cases of diabetes compared to expected and also found a correlation between the peaks of new cases of diabetes following the waves of COVID-19 in Germany [8]. The Sweet registry analyzed 17,280 T1DM cases from 2018 to 2021 and observed a rise in T1DM incidence across all 92 centers, although within the expected range of the regression line. Conversely, a

nationwide study in France failed to demonstrate increased incidence [21,22].

Multiple explanations exist for the increased frequency of T1DM cases during the pandemic years, including direct SARS-CoV-2 action on pancreatic beta cells, severe illness, psychological stress during isolation, obesogenic factors, and other yet unknown factors. Discrepancies between studies in different populations may arise from variations in T1DM incidence trends, genetic risk, timing and intensity of COVID-19 exposure, and differing containment measures [23].

COVID-19 had a severe impact on Brazil, with the infection rate in children likely underestimated due to insufficient testing. Lockdowns were implemented and public schools were closed for an extended period during the pandemic; however, in low-income, densely populated areas of Rio de Janeiro, children and their parents had close social contact with others, including those in the workforce. Additionally, vaccination in Brazil began in January 2021 for adults and expanded to adolescents aged 12 to 17 in September 2021, leaving them unprotected from COVID-19.

None of the patients were vaccinated at the time of their diabetes diagnosis, indicating that vaccination did not trigger autoimmunity in this study.

In contrast to other reports, the authors did not observe an increase in DKA frequency at diagnosis during the pandemic. DKA rates are high in Brazil, with an incidence of 42.3% in a national study involving 3591 patients (median age 19), 32.8% in a survey of 545 individuals (median age 11.98) from the studied region, and 58.8% in 274 patients (median age 7.8). There is an inverse relationship between age at diagnosis and DKA, which may explain the rates observed in this study, with a median age of 8.12 at T1DM diagnosis, which is younger than the global epidemiology average [24–30]. The disparity in these results may be due to the notably high baseline incidence of DKA in the studied population, at 62.6%, compared to 15% in a previous Brazilian study and 24.5% in Germany, which increased to 34% and 44.7%, respectively, yet remained lower than this incidence.



Brazil's testing for SARS-CoV-2 was insufficient, with restricted availability until 2021. Given the scarcity of tests when data collection began, the authors aimed to collect data on SARS-CoV-2 symptoms to estimate underreported infections and identify clinical characteristics. Symptoms of SARS-CoV-2 infection were reported in 24% of patients, and 13% of the 53 patients tested had a positive SARS-CoV-2 result before the diagnosis of diabetes. Three patients had no symptoms of SARS-CoV-2 infection but had a detectable RT-PCR for SARS-CoV-2 at admission for T1DM. A similar finding was observed in a cohort of infants, where six patients developed islet antibodies simultaneously with SARS-CoV-2 antibodies, and six others did so at their next visit after testing positive for SARS-CoV-2 [12,17].

The average time from the onset of SARS-CoV-2 symptoms to a diagnosis of diabetes was 38 days. This aligns with CDC findings of diabetes risk within three months post-COVID-19 infection and reports of increased T1DM cases in Germany following each COVID-19 wave [20,30].

The authors could not assess islet antibodies. Therefore, the authors cannot establish any causal or temporal associations between SARS-CoV-2 infection and the increase in autoimmunity. The literature presents conflicting results. A meta-analysis demonstrated an adjusted hazard ratio (HR) of 3.5 for the development of islet autoantibodies in individuals who tested positive for SARS-CoV-2, particularly those under 18 months of age [17]. In contrast, children from the TEDDY study were systematically tested for SARS-CoV-2, and did not show that COVID-19 increased T1DM antibodies [11].

The authors found a significant difference in the frequency of new T1DM cases in the third quarter of 2020 compared to 2018 and 2019, as well as between the quarters of 2020. Several studies suggest a shift in seasonal variation in the presentation of T1DM during the pandemic [22]. The typical seasonality of more cases during the winter season was delayed in Europe and North America following the lockdown early in 2020, with a peak during the summer and autumn months, returning to the previous pattern in 2021. T1DM in Brazil exhibits no clear seasonality, with no significant patterns observed before or after the pandemic. The peak of new T1DM cases in this study occurred in the 3rd quarter of 2020, shortly after the highest COVID-19 hospitalization rates in June and July 2020.

## Strengths and limitations

The present study contributes by providing evidence of the increased frequency of new diabetes cases during the pandemic in a region where data is scarce. The data were collected from multiple centers representative of the studied population, and all observed an increase in the number of children diagnosed with T1DM during the pandemic, which makes referral biases unlikely.

This study is not population-based; therefore, the authors were unable to calculate the incidence rate of pediatric T1DM. Additionally, the authors do not have access to national registries for T1DM in Brazil. Although the time frame might have been too short to exclude the cyclical variation in T1DM incidence described in Europe (20), the use of retrospective data without formal registries could increase bias in diabetes case notifications.

The absence of SARS-CoV-2 serologic testing at the time of T1DM does not allow us to infer how many patients during the pandemic period had COVID-19. However, the clinical data on COVID-19-related symptoms was important in this context because there was a decline in other respiratory infectious diseases in children during the pandemic; therefore, most symptomatic children were likely to have COVID-19. This study also highlights the clinical characteristics of cases diagnosed during the pandemic and compares them to those from previous years. Furthermore, although the authors did not perform diabetes antibody testing, all patients diagnosed during the pandemic were followed up for an average of three months after enrollment, which helped exclude transient cases of hyperglycemia or misclassification.

There was an increase in the number of cases of T1DM in children and adolescents during the COVID-19 pandemic period in a large metropolitan area population in Brazil. The authors observed a high frequency of DKA in the studied population, similar to the frequency during the pandemic period. This data should raise awareness of T1DM diagnosis in children, which could help prevent DKA, and highlight the need to allocate more resources for diabetes care in the context of an increasing frequency of cases.

## Declaration of generative AI and AI-Assisted technologies in the writing process

During the preparation of this work, the authors utilized Grammarly AI prompts to verify the text's correctness and readability. After using this tool, the authors reviewed and edited the content as necessary and took full responsibility for the final publication.

## Funding

The author(s) received no financial support for this article's research, authorship, and/or publication.

## Article information

The data supporting this study's findings are available from the corresponding author upon reasonable request.

## Conflicts of interest

The authors declare no conflicts of interest.

## Editor

C. de A.D Alvesis

## References

1. Children and COVID-19: State-level data report. [Cited <https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19->

- infections/children-and-covid-19-state-level-data-report/; 2023.
2. COVID-19 - Secretaria de Vigilância em Saúde e Ambiente - Ministério da Saúde Boletim mensal | Vigilância da covid-19 no Brasil • Março;2023.
3. COVID - coronavirus statistics - worldometer [Cited <https://www.worldometers.info/coronavirus>; 2024.
4. Woodruff RC, Campbell AP, Taylor CA, Chai SJ, Kawasaki B, Meek J, et al. Risk factors for severe COVID-19 in children. *Pediatr Pediatr*. 2022;149:e2021053418.
5. Müller JA, Groß R, Conzelmann C, Krüger J, Merle U, Steinhart J, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. *Nat Metab*. 2021;3:149–65.
6. Op de Beeck A, Eizirik DL. Viral infections in type 1 diabetes mellitus—why the  $\beta$  cells? *Nat Rev Endocrinol*. 2016;12:263–73.
7. Denina M, Trada M, Tinti D, Funicello E, Novara C, Moretto M, et al. Increase in newly diagnosed type 1 diabetes and serological evidence of recent SARS-CoV-2 infection: is there a connection? *Front Med (Lausanne)*. 2022;9:927099.
8. Kamrath C, Rosenbauer J, Eckert AJ, Siedler K, Bartelt H, Klose D, et al. Incidence of type 1 diabetes in children and adolescents during the COVID-19 pandemic in Germany: results from the DPV registry. *Diabet Care*. 2022;45:1762–71.
9. Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, et al. New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. *Diabet Care*. 2020;43:e170–1.
10. Rahmati M, Keshvari M, Mirnasuri S, Yon DK, Lee SW, Il Shin J, et al. The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: a systematic review and meta-analysis. *J Med Virol*. 2022;94:5112–27.
11. Krischer JP, Lernmark Å, Hagopian WA, Rewers MJ, McIndoe R, Toppari J, et al. SARS-CoV-2 - no increased islet autoimmunity or type 1 diabetes in teens. *N Engl J Med*. 2023;389:474–5.
12. Lugar M, Eugster A, Achenbach P, von dem Berge T, Berner R, Besser RE, et al. SARS-CoV-2 infection and development of islet autoimmunity in early childhood. *JAMA*. 2023;330:1151–60.
13. Negrato CA, Lauris JR, Saggioro IB, Corradini MC, Borges PR, Crês MC, et al. Increasing incidence of type 1 diabetes between 1986 and 2015 in Bauru, Brazil. *Diabetes Res Clin Pract*. 2017;127:198–204.
14. Ogle GD, James S, Dabelea D, Pihoker C, Svensson J, Maniam J, et al. 10th edition Global estimates of incidence of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Atlas, 183. *Diabetes Res Clin Pract*. 2022;109083.
15. Patterson CC, Harjutsalo V, Rosenbauer J, Neu A, Cinek O, Skirvarhaug T, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study. *Diabetologia*. 2019;62:408–17.
16. Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, et al. ISPAD Clinical Practice Consensus Guidelines 2018: definition, epidemiology, and classification of diabetes in children and adolescents. *Pediatr Diabetes*. 2018;19:S7–19.
17. Ssentongo P, Zhang Y, Witmer L, Chinchilli VM, Ba DM. Association of COVID-19 with diabetes: a systematic review and meta-analysis. *Sci Rep [Internet]*. 2022;12:20191.
18. Harding JL, Oviedo SA, Ali MK. The bidirectional association between diabetes and long-COVID-19: a systematic review. *Diabetes Res Clin Pract*. 2023;195:110202.
19. D'Souza D, Empringham J, Pechlivanoglou P, Uleryk EM, Cohen E, Shulman R. Incidence of diabetes in children and adolescents during the COVID-19 pandemic: a systematic review and meta-analysis. *JAMA Netw Open*. 2023;6:e2321281.
20. Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen EA, Perrine CG, et al. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged < 18 years - United States March 1, 2020-June 28, 2021 *MMWR Morb Mortal Wkly Rep*. 2022;71:59–65.
21. Mariet A-S, Petit J-M, Benzenine E, Quantin C, Bouillet B. Incidence of new-onset type 1 diabetes during Covid-19 pandemic: a French nationwide population-based study. *Diabetes Metab*. 2023;49:101425.
22. Reschke F, Lanzinger S, Herczeg V, Prahalad P, Schiaffini R, Mul D, et al. The COVID-19 pandemic affects seasonality, with increasing cases of new-onset type 1 diabetes in children, from the worldwide SWEET registry. *Diabet Care*. 2022;45:2594–601.
23. Wu Z, Wang J, Ullah R, Chen M, Huang K, Dong G, et al. COVID-19 and diabetes in children: advances and strategies. *Diabetol Metab Syndr*. 2024;16:28.
24. Rabbone I, Schiaffini R, Cherubini V, Maffei C, Scaramuzza A. Diabetes study group of the Italian society for pediatric endocrinology and diabetes. Has COVID-19 delayed the diagnosis and worsened the presentation of type 1 diabetes in children? *Diabetes Care*. 2020;43:2870–2.
25. Kamrath C, Mönkemöller K, Biester T, Rohrer TR, Warncke K, Hammersen J, et al. Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany. *JAMA*. 2020;324:801–4.
26. Kaya G, Cimcik EA, Yeşilbaş O, Bostan YE, Karagüzel G. A long-term comparison of presenting characteristics of children with newly diagnosed type 1 diabetes before and during the COVID-19 pandemic. *J Clin Res Pediatr Endocrinol*. 2022;14:267–74.
27. Negrato CA, Cobas RA, Gomes MB. Brazilian type 1 Diabetes Study Group temporal changes in the diagnosis of type 1 diabetes by diabetic ketoacidosis in Brazil: a nationwide survey. *Diabet Med*. 2012;29:1142–7.
28. de Souza L, Kraemer G de C, Koliski A, Carreiro JE, Cat MN, Lacerda LD, et al. Diabetic ketoacidosis as the initial presentation of type 1 diabetes in children and adolescents: epidemiological study in Southern Brazil. *Rev Paul Pediatr*. 2020;38:e2018204.
29. Luciano TM, Halah MP, Sarti MT, Floriano VG, da Fonseca BA, Del Roio LR, et al. DKA and new-onset type 1 diabetes in Brazilian children and adolescents during the COVID-19 pandemic. *Arch Endocrinol Metab*. 2022;66:88–91.
30. Baechle C, Eckert A, Kamrath C, Neu A, Manuwald U, Thiele-Schmitz S, et al. Incidence and presentation of new-onset type 1 diabetes in children and adolescents from Germany during the COVID-19 pandemic 2020 and 2021: current data from the DPV registry. *Diabet Res Clin Pract*. 2023;197:110559.